Valiant Laboratories Ltd

AI
Valiant Laborato Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Valiant Laboratories Ltd

₹ 121 -1.99%
04 Nov - close price
valiantlabs.in BSE: 543998 NSE: VALIANTLAB
About

Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Key Points

Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever

Website BSE NSE - BE
  • Market Cap ₹ 656 Cr.
  • Current Price ₹ 121
  • High / Low ₹ 141 / 49.5
  • Stock P/E 40.5
  • Book Value ₹ 61.2
  • Dividend Yield 0.00 %
  • ROCE 0.58 %
  • ROE -2.55 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter

Cons

  • Company has a low return on equity of -2.15% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
59.55 40.52 30.59 18.88 21.48 35.23 57.79 46.82 46.20 52.46 91.98 115.29 116.77
60.94 46.83 35.12 21.27 28.22 34.61 53.97 44.43 46.12 53.35 87.17 86.03 111.59
Operating Profit -1.39 -6.31 -4.53 -2.39 -6.74 0.62 3.82 2.39 0.08 -0.89 4.81 29.26 5.18
OPM % -2.33% -15.57% -14.81% -12.66% -31.38% 1.76% 6.61% 5.10% 0.17% -1.70% 5.23% 25.38% 4.44%
2.96 1.78 2.50 2.81 3.36 1.58 -2.31 0.66 0.87 0.63 0.17 0.86 0.11
Interest 0.02 0.02 0.02 0.05 0.01 0.06 0.05 0.07 0.14 0.68 1.01 1.07 0.96
Depreciation 0.49 0.49 0.52 0.53 0.52 0.52 0.52 0.53 0.53 2.05 2.93 2.86 3.66
Profit before tax 1.06 -5.04 -2.57 -0.16 -3.91 1.62 0.94 2.45 0.28 -2.99 1.04 26.19 0.67
Tax % 25.47% -30.75% -51.75% 218.75% 21.23% -44.44% 25.53% 25.71% 25.00% 136.12% -68.27% 19.43% 37.31%
0.79 -3.50 -1.24 -0.51 -4.74 2.35 0.70 1.82 0.20 -7.06 1.76 21.10 0.41
EPS in Rs 0.23 -0.75 -0.26 -0.11 -1.01 0.50 0.15 0.39 0.04 -1.30 0.32 3.88 0.08
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
334 182 133 237 376
299 190 138 231 338
Operating Profit 35 -8 -5 6 38
OPM % 11% -4.6% -3.5% 2.7% 10%
5 10 5 2 2
Interest 0 0 0 2 4
Depreciation 2 2 2 6 12
Profit before tax 38 -1 -2 1 25
Tax % 24% -142% 46% 525%
29 0 -2 -3 16
EPS in Rs 8.26 0.07 -0.47 -0.60 2.98
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -11%
TTM: 102%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 220%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -11%
1 Year: 45%
Return on Equity
10 Years: %
5 Years: %
3 Years: -2%
Last Year: -3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 33 43 43 54 54
Reserves 68 193 191 257 278
60 77 122 46 38
52 29 45 107 84
Total Liabilities 213 343 401 464 454
48 50 48 227 226
CWIP 1 43 156 6 6
Investments 34 38 0 26 35
130 212 197 205 187
Total Assets 213 343 401 464 454

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
56 2 1 -10
-55 -144 -53 7
-1 152 45 2
Net Cash Flow -0 10 -7 -1
Free Cash Flow 18 -44 -112 -45
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 185% -11% 25% -147%

Ratios

Consolidated / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 97 92 197 144
Inventory Days 17 22 13 84
Days Payable 62 56 128 175
Cash Conversion Cycle 52 57 82 53
Working Capital Days 70 106 156 116
ROCE % -2% -1% 1%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Paracetamol Capacity Utilisation
% of installed capacity ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Revenue from Top 5 Customers
INR million ・Standalone data
Average Realization per MT (Paracetamol)
INR per MT ・Standalone data
Domestic Revenue Share
% of total revenue ・Standalone data
Installed Paracetamol Manufacturing Capacity (Tarapur)
MT per month ・Standalone data
Paracetamol Sales Volume
MT ・Standalone data
Permanent Employees
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
7.08% 3.48% 1.89% 0.00% 0.00% 0.64% 0.63% 0.02% 0.01% 0.20% 0.00% 0.07%
0.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00% 0.00% 0.00% 0.00% 0.08%
17.54% 21.58% 23.18% 25.06% 25.06% 24.42% 23.97% 25.05% 25.05% 24.87% 25.06% 24.91%
No. of Shareholders 15,82114,91414,24915,18915,69215,03614,43215,07514,91014,65714,34114,618

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings